LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted a New Drug Application (NDA) to the Ministry of Food ...

HUC1-394 is a peptide-based eye drop for dry eyes, licensed from NOVACELL Technology. According to the company, HUC1-394 ...

Health Canada approved Eydenzelt, a biosimilar of Eylea, for multiple ophthalmic indications, based on comprehensive evidence including a phase 3 trial. The phase 3 trial demonstrated Eydenzelt's ...

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which is is the generic equivalent of RESTASIS 0.05%, a registered trademark of ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

Lid margin collarettes are common in moderate-to-severe DED, but most do not progress over time. No link was found between ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

One of the most futuristic components of Hipsley’s work is the Virtual Eye Simulation Analyzer (VESA), an AI-enabled modeling ...

Digital Edition | Journals | Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...